NEUROBO PHARMACEUTICALS INC (NRBO)

US64132R4048 - Common Stock

4.75  -0.08 (-1.66%)

Fundamental Rating

2

NRBO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 574 industry peers in the Biotechnology industry. NRBO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NRBO does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

NRBO had negative earnings in the past year.
In the past year NRBO has reported a negative cash flow from operations.
NRBO had negative earnings in each of the past 5 years.
In the past 5 years NRBO always reported negative operating cash flow.

1.2 Ratios

NRBO has a worse Return On Assets (-97.41%) than 77.76% of its industry peers.
Looking at the Return On Equity, with a value of -164.53%, NRBO is doing worse than 67.43% of the companies in the same industry.
Industry RankSector Rank
ROA -97.41%
ROE -164.53%
ROIC N/A
ROA(3y)-62.45%
ROA(5y)-121.04%
ROE(3y)-81.21%
ROE(5y)-165.85%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NRBO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

The number of shares outstanding for NRBO has been reduced compared to 1 year ago.
The number of shares outstanding for NRBO has been increased compared to 5 years ago.
NRBO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

NRBO has an Altman-Z score of -10.63. This is a bad value and indicates that NRBO is not financially healthy and even has some risk of bankruptcy.
NRBO has a worse Altman-Z score (-10.63) than 78.98% of its industry peers.
There is no outstanding debt for NRBO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.63
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.46 indicates that NRBO has no problem at all paying its short term obligations.
The Current ratio of NRBO (2.46) is worse than 73.20% of its industry peers.
A Quick Ratio of 2.46 indicates that NRBO has no problem at all paying its short term obligations.
NRBO has a Quick ratio of 2.46. This is in the lower half of the industry: NRBO underperforms 71.98% of its industry peers.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 2.46

1

3. Growth

3.1 Past

NRBO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.81%, which is quite impressive.
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NRBO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.15%
EPS Next 2Y16.88%
EPS Next 3Y13.41%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

NRBO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRBO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NRBO's earnings are expected to grow with 13.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.88%
EPS Next 3Y13.41%

0

5. Dividend

5.1 Amount

NRBO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NEUROBO PHARMACEUTICALS INC

NASDAQ:NRBO (7/17/2024, 2:26:16 PM)

4.75

-0.08 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap23.32M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.41%
ROE -164.53%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.46
Quick Ratio 2.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-8.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y